Rockwell Medical Partners With HydroCare to Distribute and Install Its Dry Acid Concentrate Mix System
Rockwell Medical Partners With HydroCare to Distribute and Install Its Dry Acid Concentrate Mix System
WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has partnered with HydroCare, a leading provider of state-of-the-art dialysis water treatment systems to healthcare facilities globally, to purchase and install the Company's dry acid concentrate mix system in dialysis water rooms. Rockwell anticipates that with these new mixer installations through HydroCare, the Company will also generate new sales related to its dry acid hemodialysis concentrates. Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's CitraPure and Dri-Sate dry acid concentrate powders.
密歇根州 WixOM--(美国商业资讯)--Rockwell Medical, Inc.(“公司”)(纳斯达克股票代码:RMTI)是一家开发、制造、商业化并向全球透析提供商分销血液透析产品组合的医疗保健公司,今天宣布,该公司已与向全球医疗机构提供最先进透析水处理系统的领先供应商HydroCare合作,在透析水中购买和安装公司的干酸浓缩混合系统房间。罗克韦尔预计,通过HydroCare安装这些新的搅拌机,该公司还将创造与其干酸血液透析浓缩液有关的新销售额。罗克韦尔医疗的 DAMX45 干酸浓缩物混合系统已获得 510 (k) 批准,只能与该公司的 CitraPure 和 Dri-Sate 干酸浓缩粉末一起使用。
"The dialysis water room is the heartbeat of the dialysis unit, housing the systems that provide highly purified water. It requires regular upkeep to stay clean and toxin-free," says Eric Cirignano, Founder and CEO of HydroCare. "At HydroCare, we focus on providing reliable dialysis water treatment systems that put patient safety first. Our product range includes large RO systems, disposables, and replacement parts. We needed a simple, easy-to-train solution for dry acid mixers, and found that and more with Rockwell Medical's 'ready-to-use' DAMX45 dry acid concentrate mix system."
“透析水室是透析装置的心跳,里面装有提供高度纯净水的系统。它需要定期维护才能保持清洁和无毒。” HydroCare创始人兼首席执行官埃里克·西里尼亚诺说。“在HydroCare,我们专注于提供可靠的透析水处理系统,将患者安全放在首位。我们的产品范围包括大型反渗透系统、一次性用品和替换部件。我们需要一种简单、易于训练的干酸混合器解决方案,在罗克韦尔医疗'即用型'的 DAMX45 干酸浓缩物混合系统中发现了这一点以及更多。”
"We are excited to partner with HydroCare to sell and install our dry acid mixers as part of their dialysis water room installations," said Tim Chole, Chief Commercial Officer at Rockwell Medical. "Our mixer is compact, quick and easy to install, and FDA-approved for Rockwell's dry acid products. Using a forced RO water pump to mix the product, our mixer enables a dialysis clinic to mix 100 gallons of acid concentrate on-site in just three minutes. We believe that this partnership with HydroCare offers us another avenue to install Rockwell's mixers into more clinics to benefit more patients."
罗克韦尔医疗首席商务官蒂姆·乔尔表示:“我们很高兴能与HydroCare合作,销售和安装我们的干酸混合器,作为其透析水室设施的一部分。”“我们的混合器结构紧凑,安装快捷方便,经美国食品药品管理局批准,适用于罗克韦尔的干酸产品。我们的混水器使用强制反渗透水泵来混合产品,使透析诊所能够在短短三分钟内在现场混合 100 加仑的浓缩酸。我们相信,与HydroCare的合作为我们提供了另一种途径,可以将罗克韦尔的混合器安装到更多诊所,使更多患者受益。”
About HydroCare
关于 HydroCare
HydroCare isn't just meeting the dialysis community's stringent water filtration standards—we're revolutionizing them. Our dialysis water system are engineered to guarantee that patients receive nothing less than the safest, most reliable water for their treatments, every single time. By integrating technologies like reverse osmosis, innovative endotoxin-retentive filters, and cutting-edge pretreatment systems, HydroCare obliterates organic and inorganic contaminants. This is how we redefine the future of dialysis water—pure, compliant, and uncompromising in quality. For more information, visit hydrocare.us.
HydroCare 不仅满足透析界严格的滤水标准,我们还在对其进行革新。我们的透析用水系统经过精心设计,可确保患者每次都能获得最安全、最可靠的治疗用水。通过整合反渗透、创新的内毒素保留过滤器和尖端预处理系统等技术,HydroCare 可以去除有机和无机污染物。这就是我们重新定义透析水未来的方式——纯净、合规、质量毫不妥协。欲了解更多信息,请访问 hydrocare.us。
About Rockwell Medical
关于罗克韦尔医疗
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient's home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work in 2023 and 2024 and named Fortune Best Workplaces in Manufacturing & Production TM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions TM . For more information, visit .
罗克韦尔医疗公司(纳斯达克股票代码:RMTI)是一家医疗保健公司,为全球透析提供商开发、制造、商业化和分销血液透析产品组合。Rockwell Medical的使命是为透析诊所及其服务的患者提供业内最佳客户服务支持的最高质量的产品。罗克韦尔专注于创新的长期增长战略,以增强其产品、流程和员工,使公司能够为医疗保健系统创造非凡的价值,并对血液透析患者的生活产生积极影响。血液透析是最常见的终末期肾脏疾病治疗形式,通常在独立的门诊透析中心、医院门诊中心、专业护理机构或患者家中进行。Rockwell Medical的产品对终末期肾脏疾病的弱势患者至关重要,该公司坚持不懈地提供无与伦比的可靠性和客户服务。罗克韦尔医疗在2023年和2024年被认证为最佳工作场所,并于2024年被评为《财富》制造与生产领域最佳工作场所Tm,致力于提供维持生命的透析解决方案Tm。欲了解更多信息,请访问。
Forward-Looking Statements
前瞻性陈述
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," "are determined," "are on track," "are resolute in our vision," or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include statements relating to generating new sales and installing the Rockwell Medical mixer into additional dialysis clinics. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.
本新闻稿中的某些陈述可能构成联邦证券法所指的 “前瞻性陈述”。诸如 “可能”、“可能”、“将”、“应该”、“相信”、“期望”、“预测”、“估计”、“继续”、“可以”、“会”、“发展”、“计划”、“潜力”、“预测”、“项目”、“打算”、“期待”、“保持信心”、“保持信心” 等词语是坚定的,” “步入正轨”、“坚定不移地实现我们的愿景”,或这些条款的否定之处,以及类似的表达,或有关意图、信念或当前期望的陈述,均为前瞻性陈述。这些声明包括与创造新销售额以及在其他透析诊所安装罗克韦尔医疗混频器有关的声明。尽管罗克韦尔医疗认为这些前瞻性陈述是合理的,但不应过分依赖任何此类前瞻性陈述,这些陈述是基于我们在本新闻稿发布之日获得的信息。这些前瞻性陈述基于当前的估计和假设,受各种风险和不确定性的影响(包括但不限于罗克韦尔医疗在美国证券交易委员会文件中列出的风险和不确定性),其中许多风险和不确定性是我们无法控制的,可能会发生变化。实际结果可能存在重大差异。风险和不确定性包括但不限于我们在截至2023年12月31日止年度的10-k表年度报告的 “风险因素” 部分中更全面地讨论的风险,因为此类描述可能会在我们向美国证券交易委员会提交的任何未来报告中进行修改或更新。除非法律要求,否则罗克韦尔医疗明确表示不承担任何更新我们的前瞻性陈述的义务。
Heather R. Hunter
SVP, Chief Corporate Affairs Officer
(248) 432-1362
IR@RockwellMed.com
希瑟·R·亨特
高级副总裁、首席企业事务官
(248) 432-1362
IR@RockwellMed.com
Source: Rockwell Medical
来源:罗克韦尔医疗